Viatem

Viatem is a biotechnology company that originated as a spin-out from the University of Birmingham and the University of Oxford, specializing in the biology of stromal cells. The company focuses on developing small molecule therapeutics designed to treat chronic inflammatory diseases by targeting fibroblasts and other cells within the tissue microenvironment. Rather than traditional immunosuppression, Viatem's approach aims to reprogram these cells to facilitate the resolution of inflammation. The company's research is grounded in the work of leading academics in rheumatology and immunology. In 2021, Viatem was acquired by the Belgian pharmaceutical company Galapagos NV to enhance its pipeline of inflammation-focused drug candidates.